TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal and Liver Disorders in ACS Infectious Disease.

November 11, 2019/Suzhou/China – TenNor Therapeutics released positive top-line results for TNP-2092 powder for injection from a phase II clinical trial conducted in the United States. TNP-2092 is currently under clinical development for the treatment of medical device associated bacterial biofilm infections. It has the potential to become the first drug approved for such infections.

February 27, 2019/Suzhou/ -- TenNor Therapeutics Limited, a clinical-stage company focused on developing differentiated infectious disease products, announced that it has received US Food and Drug Administration (FDA) Qualified Infectious Disease Product (QIDP) designation for TNP-2092 powder for injection (TNP-2092 IV), for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Catheter Related Blood Stream Infections (CRBSI) and Prosthetic Joint Infections (PJI). Benefits available under QIDP designation include priority review, fast track and 5-year extension of market exclusivity.

TenNor’s class I new drug, TNP-2198 capsule, has been approved by CDE for the initiation of clinical studies. This is TenNor’s another new pharmaceutical product entering clinical stage after TNP-2092 IV and TNP-2092 PO. TNP-2198 developed by TenNor is a novel and highly-differentiated antibiotic product, aiming at solving the major unmet clinical needs in the treatment of anaerobic and micro-aerobic bacterial infections.

TenNor held a kick-off meeting for the phase II clinical trial of TNP-2092 IV in San Francisco on Aug. 2, 2018. This product has been developed to solve the challenges of bacterial biofilm infections associated with implantable medical devices in clinic. The phase II trial will further evaluate the safety and effectiveness of the drug candidate.

The 9th China Healthcare Investment Conference (CHIC) was held on March 28-29, 2018 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, presented TenNor’s recent progress to the conference (please click this link for the presentation: TENNOR 9th CHIC Presentation).

TenNor Therapeutics held its first Clinical Advisory Meeting on TNP-2092 for the treatment of prosthetic joint infections (PJIs) during the American Association of Hip and Knee Surgeons (AAHKS) Meeting in San Francisco on May 5, 2017.

TenNor Therapeutics today announced a $25 million Series B financing led by Northern Light Venture Capital. Joining this round were current investors Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund. Proceeds will be used to advance new antibiotics into the late-stage of clinical development.